IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Leprosy

Rushikesh Keshav Gangurde[1], Nikhil Mohan Kasar[2],

Puja Motiram Thakare[3], Prof. Zahid Anwar (M. Pharm)[4]

Swami Vivekanand Sanstha's Institute of Pharmacy, Mungase Tel. Malegaon Dist. Nashik Maharashtra, 423203

Abstract:

Leprosy is a treatable disease that has been largely eradicated in many countries, including India, thanks to the widespread availability of effective and safe medications. The treatment of leprosy has evolved significantly over the years, starting with the use of chaulmoogra oil in 1915, followed by dapsone monotherapy in 1946, and eventually transitioning to multidrug therapy (MDT) in 1982. In recent decades, however, there have been reports of resistance to all first-line drugs, highlighting the need for clinical trials exploring newer, more potent drugs and their combinations to combat Mycobacterium leprae.

1. Introduction of Leprosy Disease:

Hansen's disease, commonly known as leprosy, is a persistent contagious condition primarily caused by the bacterium Mycobacterium leprae. It predominantly impacts the skin, peripheral nerves, upper respiratory tract, and eyes, causing symptoms like skin sores, nerve impairment, and muscle frailty. Without proper treatment, it may lead to significant disfigurement and lasting disability, often stemming from nerve issues affecting sensation and mobility. Despite leprosy being recognized since ancient times, it is now treatable with modern therapies. The extensive utilization of multi-drug therapy (MDT) since its introduction in 1982 has greatly advanced the eradication of the disease in numerous regions, such as India. Early identification and treatment have been pivotal in managing the transmission of leprosy and the worldwide count of leprosy is significantly decreased.

Leprosy continues to be widespread in

Through trade, war, and colonization, the disease spread worldwide, where it has become endemic in different areas. This was followed by the discovery of Mycobacterium leprae, the bacteria that cause leprosy, in 1873 and the use of antibiotic treatments leading to a mass decrease in the prevalence of the disease. Nonetheless, leprosy is still a public health problem in some regions of the globe, and therefore the need to eradicate this disease, along with combating social stigma continues.

3.Causes and Transmission of Leprosy:

Leprosy is an infectious disease caused by the slow-growing bacterium Mycobacterium leprae, which primarily affects the skin, nerves, respiratory mucosa, and eyes. Because of its long replication cycle, symptoms can take years to manifest. The bacteria preferentially attack Schwann cells causing nerve damage.

The disease is transmitted by prolonged exposure to respiratory droplets from infected people but is not highly infectious. Most people have natural immunity and casual contact does

areas, especially in parts of India, Southeast Asia, and Africa, despite the advancements made. The main mode of transmission for the disease is through respiratory droplets, although it is not highly contagious.

Leprosy's history is marked by significant social stigma, leading to isolation and discrimination. This has resulted in the marginalization of affected individuals.

This paper will explore the history, causes, symptoms, treatment, and social impacts of leprosy, as well as recent advancements in the fight against the disease.

2.History and Global Spread of Leprosy in the Middle Ages:

Leprosy, which some found had been mentioned in Egyptian, Indian and Greek texts from antiquity. Many civilizations even placed an important social stigma on it. In medieval times leprosy was often regarded as the wrath of God and lepers were shunned in leper colonies.

5.Key Points about MDT:

Thickened Nerves: Nerves that become enlarged and create pain or loss of function.

Eye Problems: Dryness, less blinking, possible blindness.

Ulcers & Infections: Chronic wound due to numbness

6.Leprosy is classified into:

Leprosy is classified as Paucibacillary (PB) and Multibacillary (MB). PB leprosy presents with few lesions and with lower bacterial presence.

Multibacillary (MB) Leprosy: More than 5 lesions, high bacteria load, severe nerve damage.

7.Diagnosis:

- **Skin Examination:** Identifying characteristic lesions with sensory loss.
- **Slit-Skin Smear Test:** Detecting Mycobacterium leprae in skin samples.

not transmit the disease. MDT renders patients non-infectious, averting onward transmission.

4. Leprosy Clinical Features and Diagnosis Symptoms:

Leprosy is a chronic infectious disease that damages the skin, peripheral nerves, and mucous membranes. Symptoms take long to develop and vary by immune response. Key symptoms include:

Skin Lesions: Fair or reddish evulsions numbing, sluggish mending.

It kills **Mycobacterium leprae**, prevents resistance, and reduces transmission.

It is provided **free of cost** by **WHO** to all affected individuals.

Early treatment prevents complications like nerve damage and deformities.

In severe cases, additional treatments may be required, such as:

- **Anti-inflammatory drugs** like **corticosteroids (prednisolone)** or **thalidomide** to manage nerve inflammation and reactions.
- **Surgery** for nerve decompression, reconstructing deformities, or correcting disabilities.

9.Management and Rehabilitation

Effective management of leprosy involves medical, social, and psychological support.

1. **Monitoring & Follow-up:**
   - Regular check-ups ensure treatment effectiveness and detect complications early.
   - Patients are advised to report any signs of nerve damage or reactions.
2. **Nerve Damage & Disability Prevention:**
   - **Physiotherapy & Occupational Therapy** help maintain muscle function.
   - **Protective footwear & dressings** prevent wounds due to numbness.
3. **Hygiene & Wound Care:**
   - Proper care of ulcers and infected areas prevents secondary infections.

- **Skin Biopsy:** Examining tissue for bacterial presence.
- **Lepromin Test:** Assessing immune response but not confirming infection.
- **Nerve Assessment:** Evaluating nerve thickening and function loss.

7. Prevention & Treatment: Early detection and **multidrug therapy (MDT)** can prevent complications and transmission. Public health efforts focus on awareness, early screening, and reducing stigma.

8.Treatment and Management of Leprosy Treatment:

Leprosy is treated effectively with Multidrug Therapy (MDT), a combination of antibiotics recommended by the **World Health Organization (WHO)**. The treatment duration depends on the type of leprosy:

- **Paucibacillary (PB) Leprosy:** Treated with Rifampicin and Dapsone for 6 months.
- **Multibacillary (MB) Leprosy:** Treated with Rifampicin**,** Dapsone**,** and Clofazimine for 12 months or longer.

11.Prevention & Public Health Initiatives

- **Early detection** through screening programs reduces transmission.
- **Vaccination research** (e.g., BCG vaccine trials) is ongoing for prevention. eliminate
- **Health education** helps reduce discrimination and encourages timely treatment.

12.Social and Psychological Impact:

Stigma and Discrimination: Explore the historical and current stigma surrounding leprosy. How does society view people with the disease, and how does it affect their lives?

Impact on Families and Communities: Discuss how those affected by leprosy face isolation, economic hardship, and mental health challenges.

Modern-Day Stigma: Mention ongoing social stigmas, even in areas where leprosy is no longer common, and how awareness campaigns help to reduce stigma.

Social and Psychological Impact of Leprosy:

Leprosy affects both physical and mental well-being, leading to **stigma, discrimination, and emotional distress**, which significantly impact the quality of life of affected individuals.

4. **Psychosocial Support & Reducing Stigma:**
    - Counselling and education help patients reintegrate into society.

10. Psychological Impact:

Awareness programs aim to misconceptions about the disease.

- **Low Self-Esteem and Depression:** Visible symptoms and rejection cause shame, anxiety, and depression.
- **Fear and Social Withdrawal:** Many self-isolate; some face suicidal thoughts due to discrimination.
- **Family Burden:** Social exclusion and financial stress affect both patients and their families.

14. Overcoming Challenges

- **Awareness and Education:** Campaigns promote early treatment and reduce stigma.
- **Mental Health Support:** Counselling and peer support improve emotional well-being.
- **Rehabilitation and Empowerment:** Vocational training and financial aid help regain independence.
- **Legal Reforms:** Steps are being taken to remove discriminatory laws and ensure inclusion.

Addressing stigma and providing **education, mental health support, and legal protection** can help leprosy patients lead dignified lives.

Leprosy in the Modern World:

Leprosy, though curable with Multidrug Therapy **(MDT)**, remains a global health issue, especially in developing **countries**.

- **Prevalence:** Over 200,000 new cases annually, mainly in India, Brazil, and Indonesia. WHO's strategy focuses on **early detection, treatment, and stigma reduction**.
- **Challenges:** Delayed diagnosis, stigma, lack of healthcare access, and drug resistance hinder eradication efforts.
- **Advances:** MDT remains effective, while new diagnostic tool**s and** vaccine research show promise.
- **Social Reforms:** Awareness campaigns, legal protections, and

13. Social Impact

- **Stigma and Discrimination:** Social isolation, denial of jobs, education, and marriage due to myths about contagion.
- **Economic Hardship:** Many lose jobs due to disabilities and discrimination, increasing financial struggles.
- **Barriers to Healthcare:** Fear of diagnosis and stigma delay medical help, worsening the condition.
- **Legal Issues:** Outdated laws restrict rights, though efforts are being made for legal reforms.

rehabilitation programs help reduce discrimination and improve patient lives.

Conclusion:

Leprosy remains a significant public health issue, despite being curable with Multidrug Therapy (MDT). The disease affects not only physical health but also has social and psychological consequences due to stigma and discrimination.

Efforts by WHO and governments focus on early detection**,** improved treatment**,** awareness campaigns**,** and policy reforms to support affected individuals. Advances in diagnostics**,** vaccine research**,** and rehabilitation programs show promise in eradicating the disease.

To achieve a leprosy-free world, continued medical progress**,** public education**,** and social inclusion are essential. Overcoming stigma and ensuring healthcare **access** will play a key role in eliminating leprosy once and for all.

References:

[1] Global leprosy situation. Wkly Epidemiol Rec 2005; 80:289 - 95.

[2]World Health Organization (WHO). (2023). Leprosy: Key Facts. Retrieved from https://www.who.int

[3]Britton, W. J., & Lockwood, D. N. (2004). Leprosy. The Lancet, 363(9416), 1209-1219. https://doi.org/10.1016/S0140-6736(04)15952-7

[4]Singh, P., & Cole, S. T.* (2011). Mycobacterium leprae: Genes, pseudogenes, and genetic diversity. Future Microbiology, 6(1),57–71. https://doi.org/10.2217/fmb.10.150

[5] Indian Journal of Dermatology, Venereology, and Leprology (IJDVL). (2021). Special issue on leprosy research and advancements.

[6] Lockwood, D. N., & Suneetha, S. (2005). Leprosy: Too complex a disease for a simple elimination paradigm. Bulletin of the World Health Organization, 83(3), 230–235.

[7] Global Leprosy Update. (2022). Progress towards zero leprosy disease burden. Weekly Epidemiological Record, 97(36), 429–440.